CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 218 enrolled
Drug / intervention
lotrafilcon A contact lenses +2 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00937105
NCT00937105Phase 4Completed

Infiltrative Events During Silicone Hydrogel Daily Contact Lens (Daily Wear Corneal Infiltrative Event (DWCIE) Study)

University Hospitals Cleveland Medical Center·interventional·Posted Jul 10, 2009·Updated Mar 10, 2014

In Brief

A Phase 4 clinical trial evaluating lotrafilcon A contact lenses, Renu Multiplus, and 1 other intervention for Myopia and 2 related conditions. Completed, enrolled 218 participants across 1 site.

Detailed Summary

This DWCIE Study is a prospective cohort study of patients fit to the FDA approved and marketed lotrafilcon A (Ciba Vision, Air Optix Night \& Day Aqua) soft contact lenses for daily wear (DW) with monthly disposal. 218 healthy myopic (nearsighted) or hyperopic (farsighted) patients with minimal or no astigmatism and no contraindications to DW lens use will be followed for 1 year. The primary outcome is the risk of development of a corneal inflammatory event (CIE) as defined by slit lamp findings and patient symptoms. The main exposure of interest is microbial contamination of study lenses.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsAlcon Research

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 10, 2009
Enrollment StartNov 1, 2009
Primary CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 17.0 years ago

Interventions

lotrafilcon A contact lensesdevice

FDA approved soft contact lenses

Renu Multiplusdevice

Clear Caredevice